Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
作者信息
Baker Emma H, Patel Kamal, Ball Jonathan, Edwards Sarah, Harrison Thomas S, Kaul Arvind, Koh Mickey, Krishna Sanjeev, Leaver Susannah, Kumar Vinodh, Forton Daniel M
机构信息
Institute of Infection and Immunity, St George's, University of London, London, UK.
Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK.
出版信息
Br J Clin Pharmacol. 2021 Mar;87(3):1584-1586. doi: 10.1111/bcp.14466. Epub 2020 Jul 14.
Abstract
摘要
相似文献
1
Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.托珠单抗用于新型冠状病毒肺炎同情用药的见解，为随机对照试验的合理设计提供参考。
Br J Clin Pharmacol. 2021 Mar;87(3):1584-1586. doi: 10.1111/bcp.14466. Epub 2020 Jul 14.
2
The shortcomings of tocilizumab in COVID-19.托珠单抗在治疗新型冠状病毒肺炎中的不足之处。
Infez Med. 2020 Dec 1;28(4):465-468.
3
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
4
Is IL-6 a key cytokine target for therapy in COVID-19?白细胞介素-6 是 COVID-19 治疗的关键细胞因子靶点吗？
Nat Rev Immunol. 2021 Jun;21(6):337-339. doi: 10.1038/s41577-021-00553-8.
5
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
6
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.托珠单抗治疗 COVID-19 诱导的细胞因子风暴和急性呼吸窘迫综合征：来自宾夕法尼亚州西部农村一级创伤中心的病例系列。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211019557. doi: 10.1177/23247096211019557.
7
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19.托珠单抗的严重不良事件：药物警戒作为 COVID-19 监测重点的辅助手段。
Br J Clin Pharmacol. 2021 Mar;87(3):1533-1540. doi: 10.1111/bcp.14459. Epub 2020 Jul 26.
8
Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series.COVID-19 肥胖患者接受托珠单抗治疗后发生过度炎症反应：一项成功的病例系列研究。
J Investig Med High Impact Case Rep. 2021 Jan-Dec;9:23247096211037442. doi: 10.1177/23247096211037442.
9
Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series.白细胞介素6抑制剂托珠单抗在日本新冠病毒相关急性呼吸窘迫综合征所致细胞因子释放综合征患者中的应用：病例系列
Respir Investig. 2020 Nov;58(6):510-512. doi: 10.1016/j.resinv.2020.09.006. Epub 2020 Oct 7.
10
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.COVID-19 病毒感染管理的 COVIRL002 试验-托珠单抗：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Sep 3;21(1):758. doi: 10.1186/s13063-020-04680-w.
引用本文的文献
1
Does tocilizumab have an effect on the clinical outcomes in COVID-19 patients? A meta-analysis of randomized control trials.托珠单抗对COVID-19患者的临床结局有影响吗？一项随机对照试验的荟萃分析。
J Pharm Policy Pract. 2023 Nov 20;16(1):151. doi: 10.1186/s40545-023-00662-w.
2
The impact of immunosuppressive therapy on secondary infections and antimicrobial use in COVID-19 inpatients: a retrospective cohort study.免疫抑制治疗对 COVID-19 住院患者继发感染和抗菌药物使用的影响：一项回顾性队列研究。
BMC Infect Dis. 2023 Nov 17;23(1):808. doi: 10.1186/s12879-023-08697-9.
3
International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions.国际层面严重疾病患者未获许可产品同情使用准入的趋势、影响因素和差异。
JAMA Health Forum. 2022 Apr 15;3(4):e220475. doi: 10.1001/jamahealthforum.2022.0475. eCollection 2022 Apr.
4
Efficacy and safety of current treatment interventions for patients with severe COVID-19 infection: A network meta-analysis of randomized controlled trials.当前治疗严重 COVID-19 感染患者的干预措施的疗效和安全性：一项随机对照试验的网络荟萃分析。
J Med Virol. 2022 Apr;94(4):1617-1626. doi: 10.1002/jmv.27512. Epub 2021 Dec 18.
本文引用的文献
1
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
2
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.COVID-19 患者严重呼吸衰竭的复杂免疫失调。
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
5
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
6
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
7
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.托西珠单抗治疗嵌合抗原受体 T 细胞引起的细胞因子释放综合征。
Expert Rev Clin Immunol. 2019 Aug;15(8):813-822. doi: 10.1080/1744666X.2019.1629904. Epub 2019 Jun 20.
8
C-reactive protein: a critical update.C反应蛋白：重要更新
J Clin Invest. 2003 Jun;111(12):1805-12. doi: 10.1172/JCI18921.
Zotero 插件